deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02867384

Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

A Randomized Phase 2 Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation

Sponsor: Dana-Farber Cancer Institute

Conditions Graft vs. Host Disease
Interventions Obinutuzumab Placebo
Updated 21 times since 2017 Last updated: Jan 31, 2026 Started: Nov 29, 2016 Primary completion: Nov 29, 2023 Completion: Nov 14, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02867384, this PHASE2 trial focuses on Graft vs. Host Disease and remains completed. Sponsored by Dana-Farber Cancer Institute, it has been updated 21 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Feb 2019 · 6 months · monthly snapshot~Feb 2019 – ~Jul 2019 · 5 months · monthly snapshot~Jul 2019 – ~Jul 2020 · 12 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Aug 2023 · 13 months · monthly snapshot~Aug 2023 – ~Jan 2024 · 5 months · monthly snapshot~Jan 2024 – ~May 2024 · 4 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Nov 2025 · 7 months · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – present · 6 months · monthly snapshot

Change History

21 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE2

  2. Nov 2025 — Feb 2026 [monthly]

    Completed PHASE2

  3. Apr 2025 — Nov 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 16 earlier versions

  1. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Aug 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jul 2022 — Aug 2023 [monthly]

    Recruiting PHASE2

  5. Apr 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  6. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  7. Sep 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  8. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  9. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  10. Jul 2019 — Jul 2020 [monthly]

    Recruiting PHASE2

  11. Feb 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  12. Aug 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  13. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  14. Jun 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  15. Feb 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE2

  16. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • Roche-Genentech
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations